Cipla Q1 preview: Pharma major to likely report low double-digit growth in PAT; margins seen to remain steady

Nifty50 constituent pharma major Cipla is scheduled to report its Q1 earnings tomorrow. Zee Business expects the company to stage a good show in April-June quarter backed by likely market share gains. The consolidated net profit at the company is seen to log double-digit growth in the quarter under review at Rs 1,106 crore as against Rs 998 crore in the previous Q1FY24 period. The revenue at the company is seen moving higher by 7 per cent on-year to Rs 6,789 crore versus Rs 6,329 crore in the same quarter last year.

The company's revenue in the US is expected to log 3.6 per cent on-year growth and come in at around $24 crore. 

EBITDA- a profitability metric is also seen to log 11 per cent on-year growth to Rs 1,653 crore versus Rs 1,494 crore in the year-ago period. 

DF sales at the company during the reporting quarter may log 7 per cent growth as per the desk estimates, while SA sales during the review quarter is expected to log 21 per cent growth on-year. Further, the desk anticipated the company's earnings may see an impact on account of divestment of its Ugandan subsidiary, QCIL, effective November 14, 2023. 

Further, the desk bakes in EU/ROW sales growth by 9 per cent during the review period.

Key monitorables

Comments related to the USFDA on Goa/Pithampur facility hold significance
Also, stakeholders will remain watchful of the manufacturing of Respules in China plant

Cipla share price performance

Ahead of its results tomorrow, the stock closed more or less flat at Rs 1,502.3 per share on the BSE. The stock in the last one year has zoomed by 43 per cent.